Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Department of Statistics, Ewha Womans University, Seoul, South Korea.
Clin Exp Pharmacol Physiol. 2022 Oct;49(10):1126-1135. doi: 10.1111/1440-1681.13695. Epub 2022 Jul 13.
We aimed to evaluate the predictive performance of previously constructed free (C ) and total (C ) cefoxitin pharmacokinetic models and the possibility of administering cefoxitin via the target-controlled infusion (TCI) method in clinical practice. Two external validation studies (N = 31 for C model, N = 30 for C model) were conducted sequentially. Cefoxitin (2 g) was dissolved in 50 mL of normal saline to give a concentration of 40 mg mL . Before skin incision, cefoxitin was infused with a TCI syringe pump. Target concentrations of free concentration and total concentration were set to 25 and 80 μg mL , respectively, which were administered throughout the surgery. Three arterial blood samples were collected to measure the total and free plasma concentrations of cefoxitin at 30, 60 and 120 min, after the start of cefoxitin administration. The predictive performance was evaluated using four parameters: inaccuracy, divergence, bias and wobble. The pooled median (95% confidence interval) biases and inaccuracies were - 45.9 (-47.3 to -44.5) and 45.9 (44.5 to 47.3) for C model (Choi_F model), and - 16.6 (-18.4 to -14.8) and 18.5 (16.7 to 20.2) for C model (Choi_T model), respectively. The predictive performance of the newly constructed model (Choi_T model), developed by adding the total concentration data measured in the external validation, was better than that of the Choi_T model. Models constructed with total concentration data were suitable for clinical use. Administering cefoxitin using the TCI method in patients maintained the free concentration above the minimal inhibitory concentration (MIC) breakpoints of the major pathogens causing surgical site infection throughout the operation period.
我们旨在评估先前构建的游离(C)和总(C)头孢西丁药代动力学模型的预测性能,以及通过靶控输注(TCI)方法在临床实践中给予头孢西丁的可能性。连续进行了两项外部验证研究(C 模型为 31 例,C 模型为 30 例)。将头孢西丁(2g)溶解在 50ml 生理盐水,使浓度达到 40mg/ml。在切开皮肤前,用 TCI 注射器泵输注头孢西丁。游离浓度和总浓度的目标浓度分别设定为 25 和 80μg/ml,在整个手术期间给予。在开始给予头孢西丁后 30、60 和 120 分钟,分别采集 3 份动脉血样,以测量头孢西丁的总血浆浓度和游离血浆浓度。使用四个参数评估预测性能:不准确性、发散性、偏差和摆动。Choi_F 模型(C 模型)的汇总中位数(95%置信区间)偏差和不准确性分别为-45.9(-47.3 至-44.5)和 45.9(44.5 至 47.3),Choi_T 模型(C 模型)分别为-16.6(-18.4 至-14.8)和 18.5(16.7 至 20.2)。通过添加外部验证中测量的总浓度数据新构建的 Choi_T 模型的预测性能优于 Choi_T 模型。使用总浓度数据构建的模型适用于临床应用。在患者中使用 TCI 方法给予头孢西丁,可使游离浓度在整个手术期间保持在引起手术部位感染的主要病原体的最小抑菌浓度(MIC) breakpoint 之上。